Class II · Moderate risk
Erythromycin Tablets
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
Is Erythromycin recalled?
Yes — there is an active recall. 6 ongoing FDA recalls mention Erythromycin (14 total). Check the affected lots below.
Most common reason: Impurity / degradation (3 of these recalls)
Recalls are matched by product description. A recall usually affects specific lots, not every package of Erythromycin. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.
Erythromycin recalls in 2026
2 initiated in 2026, 14 in total — newest first
Class II · Moderate risk
Erythromycin Tablets
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
Class II · Moderate risk
Erythromycin Ophthalmic Ointment USP
CGMP Deviations:
Class II · Moderate risk
Erythromycin Ophthalmic Ointment USP 0.5%
CGMP Deviations:
Class II · Moderate risk
Erythromycin Topical Gel USP
CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.
Class II · Moderate risk
Erythromycin Topical Gel USP
Failed Impurities/Degradation Specifications: Lot not meeting specification for Unknown Max Related Compounds.
Class II · Moderate risk
Erythromycin Topical Solution USP
Defective container: possibility for lack of seal integrity.
Class III · Low risk
Erythromycin Topical Gel
Failed Impurities/Degradation Specifications
Class III · Low risk
Erythromycin Topical Solution USP
Failed Impurities/Degradation Specifications
Class II · Moderate risk
Erythromycin Tablets
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Class II · Moderate risk
Erythromycin 2% in Cerave Cream
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class II · Moderate risk
Erythromycin Pledgets USP
Microbial Contamination of Non-Sterile Products: Active Pharmaceutical Ingredient (API) failed USP microbial tests.
Class II · Moderate risk
ERYTHROMYCIN DR EC Tablet
Labeling: Label Mixup; ERYTHROMYCIN DR EC Tablet, 250 mg may be potentially mislabeled as methylPREDNISolone, Tablet, 4 mg, NDC 00781502201, Pedigree: AD46426_10, EXP: 5/15/2014.
Class III · Low risk
Erythromycin Topical Solution USP
Chemical Contamination: This product is being recalled because trace amounts of a plasticizer (Di-Octyl Phthalate) may be present in the product.
Free recall alerts
Know the day your medication is recalled
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.